Latham & Watkins Advises Gossamer Bio in US$212 Million Private Placement Financing

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), has announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement for gross proceeds of approximately US$212 million, before deducting placement agent fees and offering expenses.

Latham & Watkins LLP represented Gossamer Bio is the transaction, with a corporate team led by San Diego partner Matt Bush, with associates Shelby Harrison and Emilie McConnachie.